Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

• Status: Completed
• Trial end date: 2016-03-28
• Target enrollment: 0
• Participant gender: All

Summary

Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye.

Exclusion Criteria:

• Pregnant or nursing women or women of child bearing potential without unless using an effective contraception

• Stroke or myocard infarction within 3 months prior to study

• History of malignancy within the past 5 years

• Uncontrolled hypertension

• Active infection or inflammation in any eye

• use of corticosteroids for at least 30 days in the last 6 months

• treatment with anti-angiogenic drugs in any eye within last 3 months

• Panretinal or focal/drid laser photocoagulation within the last few months